ERBB2 and breast carcinoma: Despite the fact that this limits the sphere of application of the model and the gradual decrease in chemotherapy notwithstanding thanks to predictive genomic tests, chemotherapy continues to be part of many women’s experience of cancer (e.g., luminal breast cancer in premenopausal or postmenopausal women with positive nodes and high-risk negative nodes, as well as in most triple-negative or HER2-positive tumors)40.